Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand

Bladder Cancer
16/09/2020

Expert Rev Clin Pharmacol. 2020 Sep 16. doi: 10.1080/17512433.2020.1823830. Online ahead of print.

ABSTRACT

INTRODUCTION: Erdafitinib is the first orally administered pan-fibroblast growth factor receptor (FGFR) kinase inhibitor approved by the Food and Drug Administration (FDA).


AREAS COVERED: Specifically binding to FGFR family (FGFR-1 to FGFR-4), erdafitinib leads to reduced cell signaling and cellular apoptosis. Coupled with the ability to bind to vascular endothelial growth factor 2 (VEGFR-2), KIT, Fms-related tyrosine kinase 4 (FLT4), platelet-derived growth factor receptor α and β (PDGFR-α and PDGFR-β), RET and colony-stimulating factor 1 receptor (CSF-1R), erdafitinib has further reported antitumor features causing cell killing.

EXPERT OPINION: In this review, we provide a comprehensive overview of erdafitinib chemical structure, pharmacologic properties and current knowledge of clinical efficacy in the treatment of locally advanced or metastatic urothelial carcinoma. This treatment, recently approved in the U.S., is available for adult patients harboring FGFR2/FGFR3 genetic alterations who progressed within 12 months of an adjuvant or neoadjuvant chemotherapy regimen including platinum or progressed during or after prior a chemotherapy regimen including platinum.